Drug Channels
NOVEMBER 17, 2023
Maria discusses the challenges patients and healthcare providers face accessing specialty therapies. To learn more about EVERSANA’s technology solution, schedule a live demo here. Read on for Maria’s insights.
H1 Blog
OCTOBER 16, 2023
Personalized Medicine New Revenue Streams: As treatments become more personalized, life sciences companies can introduce specialized drugs or therapies for niche patient groups, opening up new markets and revenue opportunities. For more information on how to integrate AI into your workflow, request a demo.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
H1 Blog
JUNE 8, 2023
To do this, they must identify unmet needs or areas of inadequacy in existing therapies, develop strategies that address those needs, and engage with the stakeholders (HCPs) who are affected by them. To learn more about how H1 can empower medical affairs teams to diversity KOLs and HCPs leveraging H1’s HCP Universe , request a demo.
H1 Blog
DECEMBER 11, 2024
Beyond diagnosis, AI will predict treatment responses, personalize therapies, and uncover new disease patterns. And, in rare diseases where patient populations are limited, AIs ability to streamline trial design and identify patients most likely to benefit from specific therapies will further accelerate rare disease treatment.
H1 Blog
MAY 4, 2023
Developing strategies focused on engaging rising stars in health equity and clinical research will help ensure that new therapies are targeted toward those most in need while also elevating public discourse surrounding evidence-based medicine practices around the world.
H1 Blog
SEPTEMBER 26, 2023
Science and medicine have no borders, but sudden, unanticipated disruptions to medical testing and clinical trials impede progress toward new breakthroughs and new therapies that millions of patients around the world hang their hope on. Request a demo of Trial Landscape.
Codon
JUNE 26, 2023
Since the last Codon Digest, I’ve published: Reasons to Be Grateful for Biotechnology (with Avadhoot Jadhav) AAV Foundations (Part I) An overview of AAV-based gene therapies, how they get made, and where they go wrong. A live demo is available online, but “it chews through OpenAI credits,” Patel says.
Expert insights. Personalized for you.
97 
Let's personalize your content